Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454344 | 0.89 | MAPT (0.61) | HTTNR1I2ALDH1A1MAPTKCNN4 | |
| SCHEMBL18172023 | 0.86 | MAPT (0.57) | HTTNR1I2ALDH1A1MAPTTP53 | |
| SCHEMBL19902387 | 0.85 | NR1I2 (0.52) | HTTNR1I2ALDH1A1MAPTTP53 | |
| SCHEMBL17452650 | 0.85 | NR1I2 (0.50) | HTTNR1I2ALDH1A1MAPTKCNN4 | |
| SCHEMBL15897945 | 0.84 | TP53 (0.66) | HTTNR1I2ALDH1A1MAPTTP53 | |
| SCHEMBL30573700 | 0.83 | TP53 (0.57) | HTTNR1I2TP53 | |
| SCHEMBL19385582 | 0.83 | TP53 (0.57) | HTTNR1I2TP53 | |
| SCHEMBL19385580 | 0.82 | NR1I2 (0.71) | NR1I2 | |
| SCHEMBL30573727 | 0.82 | NR1I2 (0.71) | NR1I2 | |
| SCHEMBL30573720 | 0.82 | NR1I2 (0.71) | NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| WO-2023205344-A1 | SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252049-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| WO-2014113620-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-24 | — | — | WO | disclosed |
| EP-2252599-A1 | TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY | Glaxo Group Limited (GB) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009115486-A1 | TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NR1I2 917/4885ALDH1A1 4413/4885 |
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | HTT 4483/4885NR1I2 2611/4885ALDH1A1 486/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NR1I2 917/4885ALDH1A1 4413/4885 |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | OXA1L, AOX1, EPX | HTT 4489/4885NR1I2 2349/4885ALDH1A1 626/4885 |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | HTT 2391/4885NR1I2 1401/4885ALDH1A1 2590/4885 |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | HTT 2375/4885NR1I2 1415/4885ALDH1A1 2535/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | HTT 4483/4885NR1I2 2611/4885ALDH1A1 486/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NR1I2 917/4885ALDH1A1 4413/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | HTT 1107/4885NR1I2 733/4885ALDH1A1 3230/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | HTT 1192/4885NR1I2 917/4885ALDH1A1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.